One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer

European Journal of Cancer

Volumn 49, Issue 14, 2013, Pages 2986-2994

  Ejlertsen, Bent ^a   Jensen, Maj Britt ^a   Elversang, Johanna ^b   Rasmussen, Birgitte B ^b   Andersson, Michael ^a   Andersen, Jørn ^c   Nielsen, Dorte L ^b   Cold, Søren ^d   Mouridsen, Henning T ^a  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adjuvant therapy; Breast cancer; Cyclophosphamide; Fluorouracil; Methotrexate; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSAL SYNDROME; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TISSUE MICROARRAY; TREATMENT DURATION;

ADJUVANT THERAPY; BREAST CANCER; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; METHOTREXATE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; POSTMENOPAUSE; REGISTRIES; TAMOXIFEN; TREATMENT OUTCOME; VOMITING;

EID: 84883055437     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.05.006     Document Type: Article

References (33)

1. S.E. Rivkin, S. Green, and B. Metch Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study J Clin Oncol 12 1994 2078 2085
2. K.I. Pritchard, A.H. Paterson, and S. Fine Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group J Clin Oncol 15 1997 2302 2311
3. D. Crivellari, M. Bonetti, and M. Castiglione-Gertsch Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII J Clin Oncol 18 2000 1412 1422
4. M. Namer, P. Fargeot, and H. Roche Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials Ann Oncol 17 2006 65 73
5. R. Peto, C. Davies, and J. Godwin Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long term outcome among 100 000 women in 123 randomised trials, Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet 379 2012 432 444
6. H.T. Mouridsen, C. Rose, and M. Overgaard Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C Acta Oncol 27 1988 699 705
7. A.S. Knoop, S.M. Bentzen, M.M. Nielsen, B.B. Rasmussen, and C. Rose Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients J Clin Oncol 19 2001 3376 3384
8. M. Overgaard, M.B. Jensen, and J. Overgaard Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial Lancet 353 1999 1641 1648
9. S. Moller, M.B. Jensen, and B. Ejlertsen The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise Acta Oncol 47 2008 506 524
10. K.L. Henriksen, B.B. Rasmussen, A.E. Lykkesfeldt, S. Moller, B. Ejlertsen, and H.T. Mouridsen Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays J Clin Pathol 60 2006 394 404
11. K.E. Olsen, H. Knudsen, and B.B. Rasmussen Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes Acta Oncol 43 2004 35 42
12. M.C. Cheang, S.K. Chia, and D. Voduc Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 2009 736 750
13. M. Schemper, and T.L. Smith A note on quantifying follow-up in studies of failure time Control Clin Trials 17 1996 343 346
14. A.A. Lazar, B.F. Cole, M. Bonetti, and R. Gelber Patterns of treatment effects in subsets of patients in clinical trials J Clin Oncol 28 2010 4539 4544
15. N. Bentzon, M. Düring, B.B. Rasmussen, H. Mouridsen, and N. Kroman Prognostic effect of estrogen receptor status across age in primary breast cancer Int J Cancer 122 2008 1089 1094
16. A. Goldhirsch, J.N. Ingle, R.D. Gelber, A.S. Coates, B. Thurlimann, and H.J. Senn Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 2009 1319 1329
17. K.V. Nielsen, B. Ejlertsen, and S. Müller Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer Breast Cancer Res Treat 127 2011 345 355
18. A.V. Lænkholm, A. Knoop, and B. Ejlertsen ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry Mol Oncol 6 2012 428 436
19. O. Pagani, S. Gelber, and E. Simoncini Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93 Breast Cancer Res Treat 116 2009 491 500
20. K.S. Albain, W.E. Barlow, and S. Shak Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 2010 55 65
21. B. Ejlertsen, H.T. Mouridsen, and M.B. Jensen Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89 Acta Oncol 47 2008 662 671
22. A. Goldhirsch, A.S. Coates, M. Colleoni, M. Castiglione-Gertsch, and R.D. Gelber Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group J Clin Oncol 4 1998 1358 1362
23. D.A. Cameron, C. Massie, G. Kerr, and R.C. Leonard Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer Br J Cancer 89 2003 1837 1842
24. M. De Laurentiis, G. Cancello, and D. D'Agostino Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol 26 2008 44 53
25. A. Gennari, M.P. Sormani, and P. Pronzato HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 2008 14 20
26. B. Dhesy-Thind, K.I. Pritchard, H. Messersmith, F. O'Malley, L. Elavathil, and M. Trudeau HER2/neu in systemic therapy for women with breast cancer: a systematic review Breast Cancer Res Treat 109 2008 209 229
27. J. Hugh, J. Hanson, and M.C. Cheang Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial J Clin Oncol 27 2009 1168 1176
28. M. Martin, A. Rodriguez-Lescure, and A. Ruiz Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer Breast Cancer Res Treat 123 2010 149 157
29. K.S. Albain, W.E. Barlow, and P.M. Ravdin Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 2055 2063
30. P.E. Goss, J.N. Ingle, and J.L. Pater Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen J Clin Oncol 26 2008 1948 1955
31. H. Mouridsen, A. Giobbie-Hurder, and A. Goldhirsch Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 2009 766 776
32. J.F. Forbes, J. Cuzick, A. Buzdar, A. Howell, J.S. Tobias, and M. Baum Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 2008 45 53
33. M. Dowsett, J. Cuzick, and J. Ingle Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 2010 509 518